Lombardi: Stock Market Commentary & Forecasts, Financial & Economic Analysis Since 1986

One of the Best Areas for Profit in this Trader’s Stock Market

Friday, November 9th, 2012
By for Profit Confidential

Best Areas for Profit in this Trader’s Stock MarketOver the last 12 months, there has been some serious wealth creation from the stock market. Now things are pulling back, because global economic reality has finally usurped the artificial enthusiasm regarding the third round of quantitative easing (QE3). (See “Warning: QE3 Rally Is Now Over.”) As we know, not all industry groups have experienced the same levels of business conditions this year. But as a stock market sector, some of the strongest wealth creation over the last 12 months has come from biotechnology stocks. The NASDAQ Composite Index, representing a lot of pure play technology stocks did well this year, but the NASDAQ Biotechnology Index did far better.

As you know, I’m not an advocate of equity investors taking up new positions in this stock market. I think the current stock market pullback has more legs, and rightly so—things aren’t so great in the world and the stock market is worried about the upcoming fiscal cliff.

I like a number of dividend-paying blue chips, but I’d hold off initiating new positions. But for risk-capital, speculative investors, one of the best areas of the stock market remains biotechnology stocks, and what I think speculators should be doing now is identifying the strongest names within the sector in anticipation of an attractive entry point for traders.

In doing so, all you need to do is pick and choose among the biotechnology stocks that compose the NASDAQ Biotechnology Index. All the best up-and-coming companies are there, and no matter what happens to the rest of the stock market or the global economy, there’s big money to be made from pharmaceuticals. Institutional investor participation within the sector continues to be high.

One of many biotechnology stocks producing massive wealth over the last two years is Alexion Pharmaceuticals, Inc. (NASDAQ/ALXN), a hugely successful company selling only one approved drug. This, my friends, is a biotechnology stock you want on your radar screen. The company’s stock chart is featured below:

alxn stock market charts

  • Still worried about the economy? Become an elite charter member of George's DAILY PROFITS and you could...

    TRIPLE YOUR MONEY IN A MONTH!

    George gave us the $2.8-billion IT infrastructure provider, up 4,745.20%; the $1.8-billion advertising agency, up 1,295.44%; and the $762-million business software company, up 1,213.19%.

    Only charter members can follow George daily.

    Learn how here!

Chart courtesy of www.StockCharts.com

Two years ago, Alexion was trading around $36.00 a share, up from $22.00 the previous year. While the rest of the stock market gyrated with an upward trend, Alexion appreciated to its all-time record high of $119.54 a share in the first week of October this year. Among large-cap biotechnology stocks, Alexion is one of only a handful that have developed a special drug to help a unique need.

The company has other drugs in development, but right now, it is selling “Soliris,” which helps in the treatment of paroxysmal nocturnal hemoglobinuria, a rare, life-threatening blood disease. According to the company, Soliris was approved in the U.S. and European Union (E.U.) in 2007, and then in Japan in 2010. I won’t go over the company’s financial results, but its revenue and earnings growth over the last few years have been extremely robust.

With the broader stock market in a meaningful consolidation (perhaps a full-blown stock market correction), Alexion’s share price is down. So far in this biotechnology stock’s history, it has accelerated in price after every meaningful retrenchment on the stock market. This is a track record I like to see.

Biotechnology stocks are not for everyone; they are fraught with high investment risk and are typically just within the purview of institutional investors. But you don’t have to be a medical doctor or scientist to be a good trader of biotechnology stocks, and that’s how you can approach the sector. Biotechnology stocks come with an inherently high degree of uncertainty, but then again, what doesn’t in this market?

VN:F [1.9.22_1171]
Rating: 2.0/10 (1 vote cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)
One of the Best Areas for Profit in this Trader’s Stock Market, 2.0 out of 10 based on 1 rating

This is an entirely free service. No credit card required.

We hate spam as much as you do.
Check out our privacy policy.

Mitchell Clark - Equity Markets Specialist, Financial AdvisorMitchell Clark, B. Comm. is a Senior Editor at Lombardi Financial specializing in large- and micro-cap stocks. He’s the editor of a variety of popular Lombardi Financial newsletters, such as Income for Life and Micro-Cap Reporter. Mitchell, who has been with Lombardi Financial for 17 years, won the Jack Madden Prize in economic history and is a long-time student of equity markets. Prior to joining Lombardi, Mitchell was as a stock broker for a large investment bank. Add Mitchell Clark to your Google+ circles

The Great Crash of 2014

A stock market crash bigger than what happened in 2008 and early 2009 is headed our way.

In fact, we are predicting this crash will be even more devastating than the 1929 crash…

…the ramifications of which will hit the economy and Americans deeper than anything we’ve ever seen.

Our 27-year-old research firm feels so strongly about this, we’ve just produced a video to warn investors called, “The Great Crash of 2014.”

In case you are not familiar with our research work on the stock market:

In late 2001, in the aftermath of 9/11, we told our clients to buy small-cap stocks. They rose about 100% after we made that call.

We were one of the first major advisors to turn bullish on gold.

Throughout 2002, we urged our readers to buy gold stocks; many of which doubled and even tripled in price.

In November of 2007, we started begging our customers to get out of the stock market. Shortly afterwards, it was widely recognized that October 2007 was the top for stocks.

We correctly predicted the crash in the stock market of 2008 and early 2009.

And in March of 2009, we started telling our readers to jump into small caps. The Russell 2000 gained about 175% from when we made that call in 2009 to today.

Many investors will find our next prediction hard to believe until they see all the proof we have to back it up.

Even if you don’t own stocks, what’s about to happen will affect you!

I urge you to be among the first to get our next major prediction.
See it here now in this just-released alarming video.